A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.

Himanshu Nagar¹, Marshall A Diven², Brady Rippon³, Christopher E Barbieri⁴, Jim C Hu⁵, Douglas S Scherr⁴, Pragya Yadav⁵, Lhaden Tshering⁵, Sharanya Chandrasekhar⁵, Sydney Wolfe⁶, Ryan Pennell⁷, Madeline Coonce⁴, Shu Ling Chen⁶, Silvia C Formenti⁵, Paul Strong⁸, Elai Davicioni⁹, Ana M Molina⁵, David M Nanus⁵, Jones T Nauseef⁵, Cora N Sternberg¹⁰, Xi K Zhou⁵, Wanni Lei⁵, Joseph R Osborne⁵, Ariel E Marciscano¹¹, Scott T Tagawa⁵

¹Weill Cornell Medicine, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: nagarh1@mskcc.org.

²NewYork-Presbyterian, Brooklyn Methodist Hospital, Brooklyn, NY, USA.

³Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.

⁴NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA.

⁵Weill Cornell Medicine, New York, NY, USA.

⁶Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.

⁷Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

⁸Hyperfine, Inc., Guilford, CT, USA.

⁹Veracyte, Inc., San Francisco, CA, USA.

¹⁰Weill Cornell Medicine, New York, NY, USA; Englander Institute for Precision Medicine, New York, NY, USA.

¹¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND AND OBJECTIVE: Some patients undergoing prostatectomy develop biochemical recurrence or have persistently detectable prostate-specific antigen level. Salvage radiotherapy (RT), delivered over ≥4 wk, is a current standard of care. Our objective was to demonstrate that salvage RT delivered in a five-fraction stereotactic body radiotherapy (SBRT) regimen does not significantly increase pat…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Hyperfine
affiliation

Other Funding

NCI NIH HHS(P50 CA211024)
United States
NCATS NIH HHS(UL1 TR002384)
United States

MeSH Terms

Humans0Male0Prostatic Neoplasms*Salvage Therapy*Patient Reported Outcome Measures0Aged0Middle Aged0Radiosurgery*Gastrointestinal Diseases*Dose Fractionation, Radiation0Male Urogenital Diseases0

Keywords

Postprostatectomy radiation therapyProstate cancerSalvage radiotherapyStereotactic body radiotherapy

Article Info

PMID: 40494733
PMCID: PMC12354193
DOI: 10.1016/j.euo.2025.05.014
Received: February 16, 2025
Accepted: May 16, 2025

How to Cite

Nagar H et al. A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution. Eur Urol Oncol2026;9(2):286-293. doi:10.1016/j.euo.2025.05.014

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.